Evidence map›Paper›PMID 25331159›Full record

ReviewProteomics. Clinical applications2015

Hold or fold--proteins in advanced heart failure and myocardial recovery.

Claudius Mahr, Rebekah L Gundry

Open access · greenAbstract readReview
In one paragraph

Review in Proteomics. Clinical applications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Myocardial Recovery.Diagnostics (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Claudius MahrDivision of Cardiology, University of Washington, Seattle, WA, USA.
Rebekah L Gundry
Medical College of Wisconsin · USUniversity of Washington · US

Funding

Surface Proteins in the Differentiation of Stem Cells to CardiomyocytesR00HL094708 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI GUNDRY, REBEKAH L. · 2011 to 2013
$702k
NHLBI NIH HHS 4R00HL094708NHLBI NIH HHS R00 HL094708
6 · The paper itself

Abstract

Advanced heart failure (AHF) describes the subset of heart failure patients refractory to conventional medical therapy. For some AHF patients, the use of mechanical circulatory support (MCS) provides an intermediary "bridge" step for transplant-eligible patients or an alternative therapy for transplant-ineligible patients. Over the past 20 years, clinical observations have revealed that approximately 1% of patients with MCS undergo significant reverse remodeling to the point where the device can be explanted. Unfortunately, it is unclear why some patients experience durable, sustained myocardial remission, while others redevelop heart failure (i.e. which hearts "hold" and which hearts "fold"). In this review, we outline unmet clinical needs related to treating patients with MCS, provide an overview of protein dynamics in the reverse-remodeling process, and propose specific areas where we expect MS and proteomic analyses will have significant impact on our understanding of disease progression, molecular mechanisms of recovery, and provide new markers with prognostic value that can positively impact patient care. Complimentary perspectives are provided with the goal of making this important topic accessible and relevant to both a clinical and basic science audience, as the intersection of these disciplines is required to advance the field.

Indexed as

AnimalsBiomarkersCardiomyopathiesDisease ProgressionHeart FailureHumansPrognosisProteomeProteomicsRecovery of FunctionBiomarkersProteomeAdvanced heart failureCirculatory supportMyocardial recoveryPluripotent stem cells

Identifiers

PMID25331159
PMCPMC4412349
OpenAlexW2074236956

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.